VIS 410

Drug Profile

VIS 410

Alternative Names: Influenza virus fusion inhibitor (VIS410) - Visterra; VIS-410

Latest Information Update: 19 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Visterra
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Influenza virus fusion inhibitors; Influenza virus haemagglutinin glycoprotein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Influenza A virus infections

Most Recent Events

  • 03 Jan 2018 Phase-II clinical trials in Influenza-A virus infections (Combination therapy) in Belgium, USA, Latvia, Estonia, Spain, Canada (IV) (NCT03040141) (EudraCT2016-004009-15)
  • 01 Nov 2017 Visterra completes a phase II trial for Influenza-A virus infections in USA, Bulgaria, Estonia, Latvia, Serbia, South Africa, and Ukraine (IV) (NCT02989194)
  • 01 Nov 2017 VIS 410 receives Fast Track designation for Influenza-A virus infections [IV,Infusion] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top